|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The involvement of the RANK/RANKL signaling in ADT-induced acceleration of bone metastasis in castration-insensitive prostate cancer was examined in a murine model using osteoprotegerin (OPG).
|
28373003 |
2017 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases.
|
27783536 |
2016 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin (OPG) is a glycoprotein that has multifaceted role and is associated with several cancer malignancies like that of bladder carcinoma, gastric carcinoma, prostate cancer, multiple myeloma and breast cancer.
|
26608463 |
2015 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The study prospectively evaluated levels of RANK, RANK-L and OPG transcripts by real-time PCR and NTX expression by ELISA in the peripheral blood of 49 consecutive patients with advanced breast, lung or prostate cancer.
|
23702841 |
2013 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have confirmed that Ad5-Δ24-sOPG-Fc-RGD replicates within and destroys prostate cancer cells and, in both murine and human coculture models, that infection of prostate cancer cells inhibits osteoclastogenesis in vitro.
|
23358109 |
2013 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We established a stable transfectant that produces high levels of OPG mRNA and protein from PC-3 human prostate cancer cells (PC3-OPG).
|
23708710 |
2013 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, TNFRSF11B rs10505346 has been implicated in PCa risk in the Cancer Genetic Markers of Susceptibility genomewide association study.
|
20204532 |
2010 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of IL-6 and OPG release by GCs may contribute to the antitumor efficacy in prostate cancer.
|
19406240 |
2009 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The variant C allele of 950 T/C in the OPG promoter may play a major role as a genetic safe guard against progression in patients with PCa.
|
18684318 |
2008 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A commonly used monoclonal antibody targeting osteoprotegerin (OPG), MAB8051, detects a truncated protein species in breast and prostate cancer cell lysates.
|
17631639 |
2007 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that the observed potentiation of antitumor activity of docetaxel by genistein in the SCID-human model of experimental bone metastasis could be mediated by regulation of OPG/RANK/RANKL/MMP-9 signaling, resulting in the inhibition of osteoclastic bone resorption and prostate cancer bone metastasis.
|
16651437 |
2006 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The increased expression of RANKL/RANK/OPG observed correlated with Gleason score, TNM stage, androgen status, and serum prostate-specific antigen (PSA) levels in the prostate cancer patients.
|
16752412 |
2006 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Crude conditioned medium (CM) from all four prostate cancer cell lines enhanced expression of the mRNA for receptor activator of NF-kappaB ligand (RANKL) in a mouse osteoblast cell line, MC3T3-E1; however, CM had no effect on expression of osteoprotegerin (OPG) mRNA.
|
15890244 |
2005 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to investigate the effects of OPG overexpression on prostate cancer cells and prostate cancer/bone cell interactions in vitro and in vivo.
|
15753366 |
2005 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CaP bone metastases were consistently immunoreactive for both OPG and RANKL compared with nonosseous metastases or primary CaP.
|
11306358 |
2001 |